Man Group’s Mineralys Therapeutics MLYS Stock Holding History

Man Group’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	59,640 +49,501	+488%	+$1.36M	﹤0.01%	1659
2026 Q1	$275K	Buy	+10,139	New	+$297K	﹤0.01%	2231
2025 Q3	–	Sell	-21,852	Closed	-$296K	–	2368
2025 Q2	$296K	Buy	21,852 +7,293	+50%	+$106K	﹤0.01%	1968
2025 Q1	$231K	Buy	+14,559	New	+$167K	﹤0.01%	1996

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Man Group's MLYS Position: Q2 2026 in Review

Man Group increased its Mineralys Therapeutics (MLYS) stake by 488% in Q2 2026, buying an estimated $1.36M and bringing the position to 59,640 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Man Group first reported a position in MLYS in Q1 2025 and has held it in 4 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Man Group held 59,640 shares of Mineralys Therapeutics worth $1.61M as of Q2 2026.
Man Group bought 49,501 Mineralys Therapeutics shares in Q2 2026, an estimated $1.36M.
Mineralys Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1659 holding.
Man Group first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 4 quarters since.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.